Form 4 for AVTX Avalo Therapeutics, Inc.
Accepted 2025-12-12 00:00:00 ET · period of report 2025-12-10 · accession 0001470831-25-000412 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-12 | 2025-12-10 | AVTX | Doyle Mittie | Chief Medical Off | F - Tax | $4.10 | -1,013 | 3,622 | -22% | -$4,153 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-10 | F | D | 1,013 | $4.10 | 3,622 | D | — | — | (F1) Includes 3,622 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction. |